Novo Nordisk Seeks FDA Approval for Combination Obesity Drug CagriSema
Event summary
- Novo Nordisk submitted a New Drug Application (NDA) to the FDA for CagriSema, a once-weekly combination of cagrilintide and semaglutide, on December 18, 2025.
- REDEFINE 1 trial data showed an average weight loss of 20.4% with CagriSema versus 3.0% with placebo, when evaluating the treatment effect regardless of patient adherence.
- CagriSema combines a novel amylin analogue (cagrilintide) with semaglutide, targeting complementary obesity pathways.
- The FDA is expected to review the application in 2026.
The big picture
Novo Nordisk's move to combine GLP-1 agonists with amylin analogues represents a strategic shift towards more comprehensive obesity treatment, moving beyond the current focus on GLP-1 RAs alone. This combination aims to address multiple pathways involved in weight regulation, potentially leading to greater efficacy. The REDEFINE trial data suggests a significant advantage over existing therapies, but the commercial success will hinge on regulatory approval and market adoption in a rapidly evolving landscape.
What we're watching
- Regulatory Risk
- The FDA review process could be impacted by increasing scrutiny of obesity drugs and their potential side effects, potentially delaying or impacting approval.
- Market Adoption
- The success of CagriSema will depend on physician and patient acceptance, which could be influenced by the drug's cost and potential gastrointestinal side effects.
- Pipeline Competition
- Novo Nordisk's market share in obesity treatment could be challenged by competing therapies in development, requiring continued innovation and differentiation.
Related topics